PHARMACEUTICAL COMBINATION INCLUDING A CIP2A SILENCING AGENT TO USE IN THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER, PRIOR TO AN IMPAIRED P53 FUNCTION

摘要

The invention is based on a finding that silencing CIP2A (KIAA1524) gene sensitizes cancer cells for apoptosis-inducing activity of certain small molecule chemotherapeutic agents. Thus, the invention is directed to a respective combination therapy, sensitization method and pharmaceutical compositions. The invention further relates to a method of selecting cancer therapy for a subject on the basis of CIP2A and p53 expression and/or protein activity in a sample obtained from said subject.